Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
NCT00574600
Completed
The purpose of this study is to evaluate the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with an experimental modified vaccinia HIV vaccine (MVA) in HIV uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
10/13/2021
Locations: Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts +3 locations
Conditions: HIV Infections
Register for Updates
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
NCT01492582
Completed
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.
Gender:
ALL
Ages:
Between 9 years and 26 years
Trial Updated:
10/07/2021
Locations: University of Alabama at Birmingham, Birmingham, Alabama +4 locations
Conditions: Cancer Survivor, Prevention of Human Papillomavirus Infection
Register for Updates
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
NCT02018458
Completed
The primary objective of this study is to determine the safety and feasibility of combining cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy. The secondary objectives of this trial are to determine pathologic complete response rates; disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients receiving DC vaccinations; and to assess the feas... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
10/07/2021
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates
The Impact of Vaccination on Severity of Illness in COVID-19
NCT04912700
Completed
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus Disease 2019 (COVID-19). Subsequently, Moderna as well as Johnson and Johnson both had vaccines receive emergency use authorization. While the Pfizer and the Moderna vaccines both utilize novel mRNA technology, Johnson and Johnson's vaccine uses a viral vector that has been... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2021
Locations: Beaumont Hospital - Royal Oak, Royal Oak, Michigan
Conditions: Covid19
Register for Updates
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
NCT02927873
Completed
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of the respiratory syncytial virus (RSV) candidate vaccine when first administered via intramuscular (IM) injection according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 23 months.
Gender:
ALL
Ages:
Between 12 months and 23 months
Trial Updated:
09/28/2021
Locations: GSK Investigational Site, Anaheim, California +23 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
H3N2 M2SR in Pediatric Population
NCT03553940
Completed
This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety and immunogenicity of a prime-boost regimen of H3N2 M2SR intranasal influenza vaccine (manufactured by FluGen) followed by licensed inactivated Quadrivalent Influenza Vaccine (QIV) boost administered intramuscularly Subjects will be enrolled in one o... Read More
Gender:
ALL
Ages:
Between 9 years and 17 years
Trial Updated:
09/23/2021
Locations: Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri
Conditions: Influenza, Influenza Immunisation
Register for Updates
Immunologic Response to FluMist vs. Flucelvax
NCT03982069
Completed
The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-21 years of age. This is a randomized controlled trial (RCT), that will assess immune response in about 440 participants (about 220 per vaccine arm) pre- and post-vaccination to FluMist (live attenuated influenza vaccine given by nasal administration) and Flucelvax (egg-free cell-culture inactivated influenza vaccine).
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
09/17/2021
Locations: General Academic Pediatrics, Pittsburgh, Pennsylvania +1 locations
Conditions: Influenza, Human, Immune Response
Register for Updates
Study of Gardasil in Mid-Adult Males (MAM)
NCT01432574
Completed
The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus \[HPV\] infection in men (HIM) Study.
Gender:
MALE
Ages:
Between 27 years and 45 years
Trial Updated:
09/13/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +1 locations
Conditions: Human Papillomavirus
Register for Updates
A Phase 2 Study to Evaluate Immune Responses of FluMist®
NCT00461981
Completed
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Gender:
ALL
Ages:
Between 12 months and 35 months
Trial Updated:
09/10/2021
Locations: Harvey Pediatrics, Jonesboro, Arkansas +18 locations
Conditions: Influenza Vaccine
Register for Updates
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
NCT03674177
Completed
The purpose of this study is to evaluate different dose levels of the investigational RSV maternal vaccine (GSK3888550A) based on safety/reactogenicity and immune response data. As this is the first time the investigational RSV maternal vaccine (GSK3888550A) is being been used in humans, this study will be performed in healthy non-pregnant women 18-45 years of age before testing in pregnant women.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/12/2021
Locations: GSK Investigational Site, Lenexa, Kansas +10 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
NCT01509846
Completed
This is a research study about an experimental (investigational) oral inactivated whole cell Shigella flexneri 2a killed vaccine (Sf2aWC). Sf2aWC is a killed vaccine that is being made to prevent disease from Shigella., which causes bloody, watery diarrhea. Infants and children living in developing countries experience the greatest consequences of this disease. The purpose of this study is to find a dose of the vaccine that is safe, tolerable, and develops an immune response. About 82 healthy ad... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/10/2021
Locations: Center for Immunization Research (CIR) at Johns Hopkins School of Public Health (JHSPH), Baltimore, Maryland +1 locations
Conditions: Shigellosis
Register for Updates
Influenza Immunity in Children
NCT02559505
Completed
This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.
Gender:
ALL
Ages:
Between 3 months and 8 years
Trial Updated:
08/05/2021
Locations: University of Rochester, Rochester, New York
Conditions: Influenza
Register for Updates